Procter & Gamble Health Limited
NSE: PGHL · Pharmaceuticals
Snapshot
Unlock Procter & Gamble Health Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Procter & Gamble Health Limited is a pharmaceutical company that manufactures and markets vitamins, minerals, and supplements. Its portfolio includes well-known consumer health brands such as Polybion, Neurobion, Evion, Nasivion, Livogen, and Seven Seas.
Business Model
The company generates revenue through the sale of over-the-counter pharmaceutical products and health supplements in India and select international markets. It operates as a subsidiary of Procter & Gamble Overseas India B.V., leveraging established global brand equity.
- Incorporation Year:1967
Growth Outlook
Growth is driven by the sustained demand for vitamins and minerals in the Indian market and the expansion of its consumer health product footprint. The company continues to focus on its core brand portfolio to maintain market share in the pharmaceutical sector.
Key Risks
- Regulatory Risk. Changes in pharmaceutical pricing policies and drug regulations by the Indian government could impact profit margins.
- Competitive Intensity. The consumer health and supplement market is highly competitive, requiring continuous investment in brand marketing and distribution.
- Supply Chain Dependency. As a subsidiary of a multinational entity, the company is susceptible to global supply chain disruptions and fluctuations in raw material costs.
Price
Start your research today
Unlock AI insights, financials, peers and live data on Procter & Gamble Health Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹1,408 Cr
TTM · standalone
NET PROFIT
₹327 Cr
TTM · standalone
EPS
₹196.94
TTM · standalone
RETURN ON EQUITY
61.2%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
77.6%
TTM · standalone
P/E
34.8x
Q4 FY26 · standalone
EV/EBITDA
23.6x
Q4 FY26 · standalone
EBITDA MARGIN
33.7%
TTM · standalone
NET PROFIT MARGIN
25.5%
Q4 FY26 · standalone
DEBT TO EQUITY
0.0x
Q4 FY26 · standalone
Peers · Pharmaceuticals
| Company | Mkt Cap (Cr) | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Procter & Gamble Health LimitedPGHL | 8,077 | 34.81 | 23.63 | 15.6% | 33.7% | 61.2% | 77.6% | +17.1% |
Strides Pharma Science LimitedSTAR | 8,494 | 17.39 | 10.36 | 4.9% | 22.1% | 21.4% | 23.5% | +14.3% |
Viyash ScientificVIYASH | 8,352 | 85.25 | 24.37 | 70.4% | 19.1% | 12.1% | 17.8% | — |
Jeena SikhoJSLL | 7,569 | 32.39 | 21.10 | — | 44.7% | 47.5% | 54.5% | +6.2% |
Akums Drugs and Pharmaceuticals Ltd.AKUMS | 7,547 | 40.97 | 15.59 | 5.8% | 14.9% | 8.2% | 13.6% | +21.6% |
Sanofi India LimitedSANOFI | 7,521 | 25.35 | 15.72 | -13.0% | 27.2% | 37.2% | 48.7% | -42.1% |
As of Q4 FY26
Financials
Procter & Gamble Health Limited
NSE: PGHL · Pharmaceuticals
Snapshot
Unlock Procter & Gamble Health Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Procter & Gamble Health Limited is a pharmaceutical company that manufactures and markets vitamins, minerals, and supplements. Its portfolio includes well-known consumer health brands such as Polybion, Neurobion, Evion, Nasivion, Livogen, and Seven Seas.
Business Model
The company generates revenue through the sale of over-the-counter pharmaceutical products and health supplements in India and select international markets. It operates as a subsidiary of Procter & Gamble Overseas India B.V., leveraging established global brand equity.
- Incorporation Year:1967
Growth Outlook
Growth is driven by the sustained demand for vitamins and minerals in the Indian market and the expansion of its consumer health product footprint. The company continues to focus on its core brand portfolio to maintain market share in the pharmaceutical sector.
Key Risks
- Regulatory Risk. Changes in pharmaceutical pricing policies and drug regulations by the Indian government could impact profit margins.
- Competitive Intensity. The consumer health and supplement market is highly competitive, requiring continuous investment in brand marketing and distribution.
- Supply Chain Dependency. As a subsidiary of a multinational entity, the company is susceptible to global supply chain disruptions and fluctuations in raw material costs.
Price
Loading…
Start your research today
Unlock AI insights, financials, peers and live data on Procter & Gamble Health Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹1,408 Cr
TTM · standalone
NET PROFIT
₹327 Cr
TTM · standalone
EPS
₹196.94
TTM · standalone
RETURN ON EQUITY
61.2%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
77.6%
TTM · standalone
P/E
34.8x
Q4 FY26 · standalone
EV/EBITDA
23.6x
Q4 FY26 · standalone
EBITDA MARGIN
33.7%
TTM · standalone
NET PROFIT MARGIN
25.5%
Q4 FY26 · standalone
DEBT TO EQUITY
0.0x
Q4 FY26 · standalone
Peers · Pharmaceuticals
As of Q4 FY26